Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase

Endocrine therapy resistance is a primary cause of clinical breast cancer treatment failure. The p38 mitogen activated protein kinase (MAPK) signaling pathway is known to promote ligand independent tumor growth and resistance to endocrine therapy. In this study, we investigated the therapeutic poten...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Antoon, James W, Bratton, Melyssa R, Guillot, Lori M, Wadsworth, Scott, Salvo, Virgilio A, Elliott, Steven, McLachlan, John A, Burow, Matthew E
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: e-Century Publishing Corporation 2012
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3410584/
https://ncbi.nlm.nih.gov/pubmed/22860234
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia